Cancer Research | Penn Today

3d illustration of a damaged and disintegrating cancer cell.

Secondary cancers following CAR T cell therapy are rare

A new Penn Medicine analysis shows that the development of any type of second cancer is a rare occurrence, and some of the earliest patients have gone on to experience long-lasting remissions of a decade or more.

New AI tool brings precision pathology for cancer into quicker, sharper focus

Researchers at Penn Medicine have developed an artificial intelligence tool to quickly analyze gene activities in medical images and provide single-cell insight into diseases in tissues and tissue microenvironments.

AI detects cancers and immunotherapy biomarker

Daiwei Zhang and Mingyao Li of the Perelman School of Medicine and colleagues have developed an AI tool called iStar that can automatically spot tumors and types of cancer that are difficult for clinicians to see or identify and can predict candidates for immunotherapy.

Penn started giving cancer patients free rides to appointments. It helped reduce no-shows and increase clinical trial enrollment

The Abramson Cancer Center is attempting to address one of the most common challenges cancer patients face: lack of transportation to critically important appointments. Robert Vonderheide and Carmen Guerra of the Perelman School of Medicine are quoted on the Ride Health initiative.

Gut health could play a role in how blood cancer patients respond to therapy

Marco Ruella of the Perelman School of Medicine says that researchers need to tackle the problems with CAR T cell therapy to increase survival rates and improve the quality of life for cancer survivors.

Godfather of mRNA vaccines reveals plans to immunize people against cancer years before tumors strike to ‘the disease from ever appearing’

Drew Weissman of the Perelman School of Medicine, who won the Nobel Prize for mRNA vaccines along with Katalin Karikó, is researching an mRNA vaccine against cancer.

A cancer vaccine, glowing tumors, lightning speed radiation: Three UPenn innovations to watch

Robert H. Vonderheide of the Perelman School of Medicine discusses three cancer treatment innovations that could be game changers for patients.

Lidocaine may be able to kill certain cancer cells by activating bitter taste receptors

A preclinical Penn Medicine study explains the previously observed anti-cancer effect of the common anesthetic drug.

colorectal screening by penn medicine students

Decentralizing cancer screenings

A Projects for Progress team in the Abramson Cancer Center continues to work with the West Philadelphia community to bring cancer screenings out of clinical settings.

Penn Medicine studies unlock new insights into gene therapy

The studies on AAV-based gene therapies in non-human primates suggest that integration into human DNA is unlikely to drive cancer mutations.

Filters